| http://www.w3.org/ns/prov#value | - Nevirapine should not be restarted following clinical hepatitis, or transaminase elevations combined with rash or other systemic symptoms, or following severe skin rash or hypersensitivity reactions.Side effects reported during postmarketing experience were associated with use of the immediate-release formulation.[Ref]DermatologicVery common (10% or more): Rash (including maculopapular erythematou
|
